Several trials are ongoing and showing some promise in the treatment of neurofibromatosis type 2 (NF2), said Bradley Welling, MD, PhD, chair of otolaryngology-head and neck surgery at Ohio State University’s College of Medicine in Columbus, during his William F. House Lecture at the Annual Spring Meeting of the American Neurotology Society.
Lapatinib, an erbB2/EGF-inhibitor, is being studied in a phase 0 trial, with enrollment nearing a close. Patients will be treated 10 days pre-operatively, and then the tumor will be removed, with the drug concentration and molecular target assessed. That trial is being led by Johns Hopkins, along with Ohio State and other centers.
An earlier phase 2 study found a 15 percent reduction in tumor volume in four of 17 patients and a 10-decibel improvement in hearing in four of 13 (Neuro Oncol. 2012;14:1163-1170).| ← Previous | | | Next → | Single Page